Ensign Group Inc (ENSG) — Titan Protect Analysis

ENSG

Ensign Group Inc

Healthcare · ·

$170.30

Data: 2026-06-03

✓ ETHICAL PASS

WEAK MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$9.7B

Total market value of the company

Trailing P/E

27.05

Premium valuation

Forward P/E

19.97

Based on estimated future earnings — lower means cheaper

Rev Growth

+18.4%

Year-over-year revenue change

Profit Margin

6.9%

How much profit the company keeps from each dollar of revenue

ROE

16.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$222.00

+30% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About Ensign Group Inc

The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The Skilled Services segment provides short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly; specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management; and standard services, such as room and board, special nutritional programs, social ser

https://ensigngroup.net

Country: United States Employees: 46,000 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.731

Good returns relative to risk taken

Kelly Fraction

0.0620

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.717

Acceptable balance between returns and drawdown risk

Annual Return

17.1%

Historical annualised return based on price data

Max Drawdown

-23.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.73

Less volatile than the market — more defensive

52W High

$218.00

22% below the year high

52W Low

$134.79

26% above the year low

Avg Volume

436,884

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

16.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$6.15

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

94.72

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

16.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

9.0%

Profit from core operations before interest and tax

Free Cash Flow

$291M

Positive — the business generates more cash than it spends

Revenue (TTM)

$5.3B

Total revenue over the last 12 months

Net Income

$363M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$230.00

Target Median

$222.00

Target Low

$210.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go